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a  b  s  t  r  a  c  t
Cold-adapted  inﬂuenza  strains  A/Leningrad/134/17/57  (H2N2)  and  B/USSR/60/69,  originally  developed
in  Russia,  have  been  reliable  master  donors  of attenuation  for preparing  live attenuated  inﬂuenza  vac-
cines  (LAIV).  The  classical  strategy  for  generating  LAIV  reassortants  is robust,  but has  some  disadvantages.
The  generation  of reassortants  requires  at least  3 passages  under  selective  conditions  after  co-infection;
each  of  these  selective  passages  takes  six days.  Screening  the  reassortants  for a  genomic  composition
traditionally  starts  after  a second  limiting  dilution  cloning  procedure,  and the  number  of  suitable  reas-
sortants  is limited.  We  developed  a new  approach  to shorten  process  of  preparing  LAIV  seed  viruses.
Introducing  the  genotyping  of  reassortants  by  pyrosequencing  and  monitoring  sequence  integrity  of sur-
face  antigens  starting  at the  ﬁrst  selective  passage  allowed  speciﬁc  selection  of suitable  reassortants  for
the  next  cloning  procedure  and  also  eliminate  one  of  the group  selective  passage  in  vaccine  candidate
generation.  Homogeneity  analysis  conﬁrmed  that  reducing  the  number  of selective  passages  didn’t  affect
the quality  of  LAIV  seed  viruses.  Finally,  the two-way  hemagglutination  inhibition  test, implemented  for
all the ﬁnal  seed  viruses,  conﬁrmed  that  any  amino  acid  substitutions  acquired  by reassortants  during
egg  propagation  didn’t  affect  antigenicity  of  the vaccine.  Our new  strategy  reduces  the  time  required  to
generate  a  vaccine  and was  used  to  generate  seasonal  LAIVs  candidates  for the  2012/2013,  2014/2015,
and  2015/2016  seasons  more  rapidly.
evierPublished  by Els
. Introduction
Vaccination is the most effective method for preventing
nﬂuenza virus infection (Fiore et al., 2009). Inﬂuenza vaccines are
ost protective when the component strains antigenically match
iruses circulating in the population. Seasonal inﬂuenza vaccines
ontain inﬂuenza A/H1N1, A/H3N2, and 2 types of inﬂuenza B virus,
ictoria and Yamagata lineage. In addition, vaccine seed strains
gainst avian H5, H7, and H9 viruses are produced for pandemic
reparedness purposes.
The two major types of inﬂuenza vaccines licensed for human
se are: inactivated inﬂuenza vaccine, which is injected, and
ive attenuated inﬂuenza vaccine (LAIV), which is administered
∗ Corresponding author. Tel.: +1 404 639 0440; fax: +1 404 639 2350.
E-mail address: tbousse@cdc.gov (T. Bousse).
ttp://dx.doi.org/10.1016/j.jviromet.2015.10.009
166-0934/Published by Elsevier B.V. This is an open access article under the CC BY-NC-N B.V.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
intranasally. The LAIV seed viruses are reassortants, which supply
the appropriate surface protein hemagglutinin (HA) and neu-
raminidase (NA) genes from seasonal isolates, and internal genes
from cold adapted type A or type B master donor viruses (MDV),
which provide cold adaptation, temperature sensitivity, and atten-
uation phenotypes. These phenotypic characteristics enable the
LAIV reassortants to replicate efﬁciently in cooler temperatures,
restrict replication to the upper respiratory tract and attenuate the
virus (Maassab and Bryant, 1999; Murphy and Coelingh, 2002).
LAIVs confer protection by inducing the development of neutral-
izing anti-HA antibodies, (Belshe et al., 2000; Cox et al., 2004;
Gerhard, 2001), mucosal cellular responses and can provide het-
erosubtypic protection (Epstein and Price, 2010; Haaheim and Katz,
2011; He et al., 2006; Hoft et al., 2011).
LAIVs have been an effective public health tool for years in
the Russian Federation (Aleksandrova, 1977; Rudenko et al., 1996;
Smorodintsen et al., 1965) and the USA (Ambrose et al., 2008;
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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andell et al., 2011; Maassab and Bryant, 1999; Murphy and
oelingh, 2002). Two types of LAIVs are available commercially.
he ﬁrst, licensed as FluMist (MedImmune, Inc.), is based on A/Ann
rbor/6/60 inﬂuenza A and B/Ann Arbor/1/66 inﬂuenza B; it is
urrently produced using seed viruses made by reverse genetics
Ambrose et al., 2008; Jin and Chen, 2014). The LAIVs based on
ussian MDV  strains are made using seed viruses produced by con-
entional reassortment in eggs (Aleksandrova, 1977; Kiseleva et al.,
007, 2014). Russian LAIVs were developed and used safely for
ore than 50 years in Russia, and recently, through cooperation
ith WHO, their production and use has been expanded interna-
ionally (Neuzil et al., 2012; Rudenko et al., 2011). The preferable
ethod approved by WHO  for seasonal LAIV seed viruses can-
idates preparation is reassortment in eggs, due to intellectual
roperty issues currently present for reverse genetics generated
AIV vaccines, the production of such vaccines could be costly,
hich is a concern for developing countries manufacturers (http://
ww.who.int/phi/Day1 Session3 PATH Marks.pdf).
The protocol for generating LAIVs based on Russian MDVs by
onventional reassortment was originally developed at the Insti-
ute of Experimental Medicine (IEM), St. Petersburg, Russia. The
rotocol includes 2 selective passages and 1 cloning step performed
t selective conditions, in the presence of anti-serum against MDV
nd at low temperature (25 ◦C) to allow the correct 6:2 reassor-
ants to dominate the pool. However, even under such robust
elective pressure, variability of the gene segments donated by the
old-adapted donor in the vaccine reassortants was often observed
Ghendon et al., 1981; Kiseleva et al., 2007, 2014; Medvedeva
t al., 1983). It was also noted that most viruses circulating prior
o the year 2000 readily reassorted with MDVs; in contrast, vac-
ine seed strains based on circulating human viruses after the year
000 were much more difﬁcult to obtain. Only 11–14% of reassor-
ants derived from post-2000 viruses using standard techniques
ossessed the desired NA, and the percentage of M and NS gene seg-
ents derived from MDVs was also relatively low (Kiseleva et al.,
014). The obstacles in developing current LAIV candidate vaccine
eeds prompted us to optimize the current protocol to increase
he yield of the desired 6:2 reassortants and expedite the LAIV
eed virus production without compromising the quality of the
roduct.
. Materials and methods
.1. Viruses
A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 MDV  were
rovided by BioDiem (Australia). Seasonal inﬂuenza isolates prop-
gated in 9- to 11-day-old embryonated eggs A/Texas/50/2012
H3N2), B/Massachusetts/02/2012 (Yamagata), A/Anhui/01/2013
H7N9), B/Texas/02/2013 (Victoria), A/Palau/6759/2014 (H3N2),
/Switzerland/9715293/2013 (H3N2), B/Phuket/3073/2013 (Yam-
gata), and A/North Carolina/13/2014 (H3N2) were obtained from
DC, Atlanta, USA. For vaccine preparation speciﬁc pathogen free
SPF) eggs (Charles River Laboratories Inc., USA) were used.
.2. The conventional IEM method of reassortment
The eggs were co-inoculated with equal doses (6 log10 of EID50)
f MDV  and seasonal isolate. Co-inoculated viruses allowed to prop-
gate and reassort at 32 ◦C for 48 or 72 h for type A and type B
nﬂuenza, respectively. The progeny of the co-inoculation subjected
urther to the two group selective passages and one cloning by lim-
ting dilution procedure under selective condition—temperature
f 25 ◦C and the presence of serum against MDV. Usu-
lly, ﬁve chicken eggs are inoculated with pooled allantoiccal Methods 227 (2016) 33–39
ﬂuids from the co-inoculation step, which was  incubated overnight
with antisera against MDV. A serum dilution with a ﬁnal HI titer of
1:60 (experimentally determined to efﬁciently neutralize MDV  but
not viruses containing the desired parental HA) was  used. The pres-
ence of virus in the progeny of infected eggs can be detected by the
HA assay after each step of vaccine generation. If HA titer could not
be detected after selective passaging at 25 ◦C, then a “blind” pas-
sage (32 ◦C without serum, 2 days for inﬂuenza type A, or 3 days
for type B) was  performed. After the blind passage the progenies
from all the positive eggs pooled again and used to infect eggs at the
same conditions (second selective passage). The progeny from the
second selective is pooled and then serially diluted 10-fold (from
10−1 to 10−7) using serum against the MDV  as a diluent (ﬁve eggs
were inoculated with each virus dilution) and incubated at 25 ◦C
for 6 days. From the eggs infected with the last positive limiting
dilution with detectable HA titers 2–3 eggs are selected. The second
cloning takes place at 32 ◦C in the presence of anti-MDV serum. The
cloned progeny is then genotyped to ﬁnd the reassortants contain-
ing the 6:2 genome composition (Desheva Iu et al., 2007; Kiseleva
et al., 2011a,b). After a 6:2 reassortant is found, additional rounds
of cloning are performed in order to enhance the purity of the reas-
sortant virus progeny. Usually, the number of 6:2 reassortants is
very limited. If no 6:2 reassortants are detected after the second
cloning, reassortment must be started anew.
2.3. Hemagglutination (HA) and hemagglutination inhibition (HI)
HA and HI assays were performed using 0.5% turkey or 0.75%
guinea pig red blood cells (Klimov et al., 2012; WHO, 2011). Fer-
ret serum against MDV  and parental inﬂuenza isolates was  raised
and used in HI to determine the origin of the HA protein in the
reassortant clones.
2.4. Two-way HI test
To determine the antigenic relationship between the parental
reference virus and the LAIV reassortants generated, ferret anti-
sera were raised against both parental contemporary human
isolates and candidate LAIV reassortants for use in the HI analy-
sis (WHO, 2011). Reassortant viruses were considered consistent
with parental isolate if the heterologous titer was within a 2-fold
of the homologous HI titer of the parental reference isolate.
2.5. Genotyping of reassortants
Genomic composition of the reassortant inﬂuenza viruses was
assessed by pyrosequencing as described previously (Shcherbik
et al., 2014b). Brieﬂy, cDNA was produced from viral RNA with
gene speciﬁc sets of primers in which either the forward or
reverse primer was  biotinylated. The biotinylated amplicons were
bound to streptavidin-coated beads and subjected to denatura-
tion and washing to generate single stranded DNAs, which were
then annealed with pyrosequencing primer, designed to detect
the strain-speciﬁc signature nucleotides. Pyrosequencing reactions
were performed with the PyroMark Gold enzyme, substrate and
nucleotides using the PyroMark ID instrument (Qiagen). Sequence
results were obtained in the form of pyrograms and analyzed using
visual interpretation and the PyroMark Q96 software (Qiagen).
2.6. Genetic homogeneity analysisGenetic homogeneity analysis of the LAIV seed viruses was per-
formed using real time RT-PCR as described previously (Shcherbik
et al., 2014a).
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.7. Genomic analysis
Complete cDNAs for each segment (PB2, PB1, PA, HA, NP,
A, M,  and NS) of the LAIV candidates were reverse transcribed
sing gene segment-speciﬁc primers and sequenced by stan-
ard Sanger technique. The sequences of HA and NA genes
ere deposited in the inﬂuenza sequence EpiFlu Database of
ISAID (http://platform.gisaid.org). Accession numbers are: for
/Anhui/1/2013-CDC-LV7A (H7N9), EPI516488 and EPI516487;
or B/Texas/02/2013-CDC-LV8B (Victoria lineage), EPI516490
nd EPI516489; for A/Switzerland/9715293/2013-CDC-LV10A
H3N2), EPI543739 and EPI543740; for B/Phuket/3073/2013-
DC-LV11B (Yamagata), EPI573303 and EPI573304; for A/North
arolina/13/2014-CDC-LV12A (H3N2), EPI573305 and EPI573306.
. Results
.1. Screening LAIV reassortants at each step of vaccine
eneration
The generation of 6:2 LAIV reassortants by traditional IEM pro-
ocol (described in Materials and Methods) from co-infection to
enotyping after second cloning procedure takes usually 32 days
or inﬂuenza A and 39 days for inﬂuenza B (Table 1). In order to
mprove and accelerate the process of generation of reassortants
ith the suitable genomic composition, several changes to the IEM
rotocol were introduced. The screening analysis was performed
t each step of vaccine generation starting from the ﬁrst selective
assage in order to choose the most suitable candidates for the next
imiting dilution cloning procedure. The sequencing of HA gene of
AIV reassortants at each cloning step of vaccine generation was
lso introduced to monitor undesired changes.
The reassortment between MDV-A and A/North Car-
lina/13/2014 (H3N2) (NC/13) an A/Switzerland/9715293/
013-like virus, the vaccine candidate recommended by WHO  for
he 2015–2016 season in the Northern hemisphere, is presented
s an example. The eggs were co-infected with equal doses of each
irus. The progeny of the co-infection was subjected to the ﬁrst
elective passage in the presence of anti-MDV-A sera at 25 ◦C for
able 1
ime ﬂow of LAIV seed virus generation and techniques used for selection of reassortants
Steps in IEM protocol Techniques used in IEM protocol St
1. Co-infection of WT  and MDV,
32 ◦C (2 or 3 days)
1
3
2.  Selective passage 1, 25 ◦C (6
days)
2
d
3.  Blind passage, 32 ◦C (2 or 3 days) 3
4.  Selective passage 2, 25 ◦C (6
days)
5. Blind passage, 32 ◦C (2 or 3 days)
6. First cloning 25 ◦C, (6 days) 4
7.  Blind passage, 32 ◦C (2 or 3 days) 7a. High growth reassortant
selection by HA assay, HI assay for
detection of HA origin, selection of
egg(s) for further cloning
5
8.  Second cloning, 32 ◦C (2 or 3
days)
8a. HA origin by HI assay,
genotyping other genes by RT-PCR
RFLP, selection of 6:2 reassortant
6
d
9.  Third and fourth cloning 32 ◦C, (4
or 6 days total)
7
o
10.  Ampliﬁcation
Inﬂuenza A 32 days
Inﬂuenza B 39 days
10a. Full genome sequencing 8
In
Incal Methods 227 (2016) 33–39 35
6 days. Since no HA activity was detected after the ﬁrst selective
passage, a blind passage was  done at 32 ◦C for 2 days. The progeny
of the blind passage were then analyzed using the HI assay with
sera raised against parental NC/13 virus or the MDV. Progeny
from 5/5 of the inoculated eggs showed inhibition by sera against
parental but not by sera against the MDV, indicating that the HA
gene segments of the progeny virus were predominantly of the
desired parental NC/13 origin.
Following the traditional IEM protocol, we would combine all
the progeny from the ﬁrst selective passage to infect ﬁve new eggs
for a second selective passage. Using our modiﬁed protocol, how-
ever, we screened the progeny harvested from individual eggs after
the ﬁrst passage using the pyrosequencing assay. Pyrosequencing
is sequencing by synthesis method, where the peak heights in the
pyrograms reﬂects the number of each nucleotide incorporated and
“signature peaks” represent the percentage of each cDNA species
present in the mixture. Partial sequences of RT-PCR amplicon’s of
RNA isolated from allantoic ﬂuid after the ﬁrst selective passage
were obtained for all genes and showed that NC/13 NA was preva-
lent in all eggs (Fig. 1A), while PB2, PB1, PA, NP, and M were present
in a mixed population (PB2 gene is shown in Fig. 1B). The NS gene
segment was predominantly of undesired NC/13 origin in the reas-
sortants from all eggs (Fig. 1C). However, the progeny of egg 21 had
the highest enrichment of the desired origins of all internal virus
genes segments (e.g., PB2 and NS pyrograms Fig. 1).
The progeny of egg 21 was  subjected to the ﬁrst cloning step
under selective conditions (serum to MDV, 25 ◦C), omitting the
second selective passage. Screening revealed that all 15 clones
from the ﬁrst cloning of egg 21 had the correct NC/13 origin
for NA gene segment. One biological clone was the correct 6:2
reassortant, and another had a 5:3 genome composition (with HA,
NA, and M originating from the NC/13 virus). All other clones had a
mixed populations for internal protein coding gene segments, with
MDV  gene segments (including NS) prevailing over NC/13 gene
segments in 7 clones. If we had not detected a 6:2 reassortant at
this step, one of the clones with a higher proportion of MDV  gene
segments would have been selected for further cloning by limiting
dilution until a 6:2 reassortant could be identiﬁed. The selected
6:2 reassortant was subjected to two  additional rounds of cloning
.
eps in modiﬁed protocol Techniques used in modiﬁed protocol
. Co-infection of WT and MDV,
2 ◦C (2 or 3 days)
. Selective passage 1, 25 ◦C (6
ays)
. Blind passage, 32 ◦C (2 or 3 days) 3a. HI assay for detection of HA origin,
pyrosequencing of other genes, HA,  NA
sequencing; selection of the egg(s) with
the highest enrichment of the desired
genes and suitable HA, NA sequences
. First cloning, 25 ◦C (6 days)
. Blind passage, 32 ◦C (2 or 3 days) 5a. Pyrosequencing, HA, NA
sequencing, selection of the egg(s)
with the highest enrichment of the
desired genes
. Second cloning, 32 ◦C (2 or 3
ays)
6a. Pyrosequencing, HA, NA
sequencing, selection of 6:2 reassortant
. Third and fourth cloning, 32 ◦C (4
r 6 days total)
7a. HA, NA sequencing at each cloning
step
. Ampliﬁcation
ﬂuenza A 24 days
ﬂuenza B 30 days
8a. Full genome sequencing
36 S. Shcherbik et al. / Journal of Virological Methods 227 (2016) 33–39
Fig. 1. Partial pyrograms of neuraminidase (NA) (A), PB2 (B), and NS (C) RNA from eggs after the ﬁrst selective passage (eggs 21, 22, and 23 are shown) after co-infection
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ignature peaks of genes on undesired origin in a mixed reassortants pool.
rocedure followed by the ampliﬁcation step. We  successfully used
his strategy to generate eight LAIV seed viruses listed in Table 3.
In parallel, a second selective passage (a step required by the tra-
itional IEM protocol) was also performed on the progeny from the
rst selective passage of the above example. Analysis of the progeny
rom the second selective passage revealed that most of the inter-
al gene segments (PA, PB1, PB2, M,  and NP) were of MDV  origin
PB2 gene is shown in Fig. 2A; compare peaks marked by green
rrows in 2A and 1B). However, the amount of the desired MDV  NS
ene was lower than in reassortants from the ﬁrst selective passage
Fig. 2B; compare peaks marked by green arrows in Figs. 1C and 2B),
llustrating that biological cloning from selected eggs after the ﬁrst
elective passage not only saves time but increases one’s ability
o select for the desired reassortant. As recommended by the cur-
ent IEM protocol, the progeny from the second selective passage
ere combined, and cloning by endpoint dilution under selective
onditions (25 ◦C, serum to MDV) was performed. Genotyping the
lones obtained showed that the internal gene segments were still mixed population, with NC/13 NS gene segment prevalent in all
lones. These demonstrated that the second selective passage does
ot ensure higher yields of the desired internal gene segments. Sim-
lar results were observed when we generated the LAIV candidate origin (NA—A/North Carolina/13/2014, internal genes—MDV), red arrows indicate
for A/Victoria/361/2011-CDC-LV1 (H3N2) where after the second
selective passage none of the clones from the second cloning step
had the desired NS gene segment of MDV  origin. Likewise, during
generation of B/Texas/6/2011-CDC-LV2B (Yamagata lineage), none
of the clones analyzed had NA of the desired parental contemporary
virus origin.
Our results showed that genotyping at each step of vaccine gen-
eration, starting from the ﬁrst selective passage to select the best
candidate for the subsequent cloning procedure, allowed us to omit
the second selective passage from the protocol and to accelerate the
generation of the desired 6:2 LAIV seed virus (Table 1).
3.2. Sequencing the HA gene of LAIV reassortants at each cloning
step of vaccine generation
The ﬁrst virus cloning step in our modiﬁed LAIV vaccine
candidates generation strategy enables selection of several
virus progenies suitable for the subsequent cloning procedure,
therefore, sequencing the HA and NA gene segments of selected
clones should be considered at this step to determine the most
appropriate candidates for further cloning. As an example from our
studies, during generation of LAIV seed virus for A/Texas/50/2012
S. Shcherbik et al. / Journal of Virological Methods 227 (2016) 33–39 37
Fig. 2. Partial pyrograms of PB2 (A) and NS (B) gene RNA from eggs after the second selective
and  MDV. Green arrows indicate signature peaks of desired origin (MDV), red arrows ind
Table 2
Amino acid changes in HA and NA of intermediate clones during the generation of
A/Texas/50/2012-CDC-LV6A.
Clone no. 4162 4163 4171 4186
(
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t
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b
t
vHA  changes I226N I226(I/N) H156Q I226N
NA  changes S334T None None None
H3N2), we identiﬁed 4 clones possessing desired HA and NA gene
egments and high proportions of internal MDV  gene segments.
rogeny of egg 4171 was the best candidate for further cloning as
ne with the highest proportion of MDV  internal gene segments.
owever, sequencing revealed that candidate 4171 had a H156Q
ubstitution in HA sequence (Table 2); this substitution known to
ffect antigenicity of other H3N2 inﬂuenza viruses and vaccines
Barr et al., 2014; Kodihalli et al., 1995; Skowronski et al., 2014).
nstead, candidate 4162, which had the egg-adapted mutation
226N (not known to affect antigenicity) was selected for further
loning to obtain genetically homogeneous 6:2 reassortants.
he HA and NA gene segments were sequenced at each limiting
ilution step to verify the lack of amino acid substitutions in these
ene segments.
The amino acid changes in HA and NA proteins of the LAIV
eed viruses generated in the present study are summarized in
able 2. None of the reassortants had amino acid changes in the
nternal segments originating from MDV. Additionally, all LAIV
eassortants showed high virus titer at the optimal temperature
f 32 ◦C, very low titer at 38–39 ◦C, and less than 3 log10-fold
ecrease in replication at 25 ◦C compared to 32 ◦C, conﬁrming their
emperature-sensitive and cold-adapted phenotypes (Table 3).
.3. Quality control of the LAIV seed virusesThe reassortant virus has to be fully characterized in order to
ecome a master seed virus for vaccine production, WHO  outlines
he requirements for complete characterization of live attenuated
accine master seed virus (WHO, 2013). To ensure that the quality passage (eggs 2–21, 2–22, and 2–23) after co-infection of A/North Carolina/13/2014
icate signature peaks of A/North Carolina/13/2014 in a mixed reassortants pool.
of the LAIV seed viruses obtained using our alternative reassort-
ment strategy was not compromised, we  used real-time RT-PCR
to test homogeneity of each reassortant (Shcherbik et al., 2014a).
Genetic homogeneity of reassortant viruses listed in Table 3 were
analyzed using RNA isolated from progeny of infected eggs corre-
sponding to 105 EID50/per reaction. For all reassortants, the positive
signals were detected only with primers/probe speciﬁc for internal
gene segments of MDV  and HA and NA gene segments of desired
parental viruses (data not shown). During vaccine manufacturing,
the number of passages the LAIV candidate virus undergoes should
not exceed 4–5 (Buonagurio et al., 2006). The desired 6:2 genome
composition of the LAIV seed viruses was  conﬁrmed after 5 more
passages in eggs using real time RT-PCR and complete genome
sequence analysis. Sequencing revealed no nucleotide substitu-
tions in all gene segments during these additional passages in all
tested seed viruses. Thus, the genomic composition of all the LAIV
seed viruses generated (Table 3) remained stable even after addi-
tional passaging in hen’s eggs.
To ensure that these mutations acquired during LAIV generation
do not alter antigenicity, two-way HI assays have been imple-
mented as a mandatory requirement for characterization of vaccine
seed viruses. That is, the reassortant should be strongly inhibited
by serum raised against the contemporary parental virus, and the
same parental virus should be strongly inhibited by ferret serum
raised against the LAIV virus. Reassortant viruses are considered
consistent with the parental reference virus antigenically if the het-
erologous HI titer is within a 2-fold difference of the homologous HI
titer (Barr et al., 2010; Katz et al., 2011). All of the LAIV seed viruses
listed in Table 3 were antigenically consistent with their parental
reference viruses, and therefore successfully passed the two-way
HI tests.4. Discussion
The conventional reassortment procedure was  developed and
successfully used for years at the IEM, Russia, to make LAIV
38 S. Shcherbik et al. / Journal of Virological Methods 227 (2016) 33–39
Table 3
Genetic and phenotypic characteristics of LAIV seed viruses.
Vaccine seed virus HA changes NA changes log10 EID50/mL  32 ◦C log10 EID50/mL 25 ◦C log10 EID50/mL 38 ◦C
B/Massachusetts/02/2012-CDC-LV5B (Yamagata lineage) None None 9.5 6.2 0
A/Texas/50/2012-CDC-LV6A (H3N2) I226N S334T 9.2 6.2 0
A/Anhui/01/2013-CDC-LV7A (H7N9) N123D, N149D* T10I 9.9 6.4 2.7
B/Texas/02/2013-CDC-LV8B (Victoria lineage) I197N None 9.5 6.3 0
A/Palau/6759/2014-CDC-LV9A (H3N2) S219Y None 9.3 6.2 2.0
A/Switzerland/9715293/2013-CDC-LV10A (H3N2) S219Y None 8.7 5.7 1.7
None
None
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cB/Phuket/3073/2013-CDC-LV11B (Yamagata lineage) N197D 
A/North Carolina/13/2014-CDC-LV12A (H3N2) S219F 
eed reassortants (Aleksandrova, 1977; Medvedeva et al., 1983;
olezhaev et al., 1978). The traditional procedure for LAIV gener-
tion is robust but has some disadvantages. It is time-consuming,
s the selection steps are lengthy. The genome composition of the
eassortants is only screened after the second cloning procedure,
enome combinations other than the 6:2 dominate in the reassor-
ant populations of LAIV seed viruses prepared using the traditional
cheme (Kiseleva et al., 2007), especially for viruses that emerged
fter the year 2000 (Kiseleva et al., 2014). Another drawback of the
rotocol is the lack of HA sequence monitoring during LAIV gen-
ration, since additional egg-adapted mutations can accumulate in
he HA gene which may  affect antigenicity of the ﬁnal reassortant
irus.
To reduce the duration of LAIV seed virus generation and
mprove the yield of 6:2 reassortants without affecting antigenicity,
e considered a few steps in the protocol for possible alteration.
ere, we demonstrate that genotyping the reassortants at ear-
ier stages of LAIV preparation is an important advantage over
he current procedure. Genotyping by pyrosequencing is semi-
uantitative and allows the assessment of the relative amounts of
ene segments of the desired origin in allantoic ﬂuid (Shcherbik
t al., 2014b). This enables rapid selection of desired reassortants at
arlier stages of the process. Our results demonstrate that the sec-
nd selective step in the procedure could be eliminated since it does
ot ensure higher yields of desired gene segments (Fig. 2), and this
ould saves up to two weeks in a demanding vaccine preparation
rocess (Table 1).
Monitoring the virus sequences for changes which could be
ntroduced during egg-based vaccine production is also critical for
accine effectiveness. Often egg adaptation of human inﬂuenza
iruses results in amino acid changes in or near receptor-binding
ite, which is located on the head region of the HA glycopro-
ein. Some egg adaptations dramatically alter virus antigenicity,
mmunogenicity, and vaccine efﬁcacy (Chen et al., 2010; Katz and
ebster, 1989; Kodihalli et al., 1995; Skowronski et al., 2014). Low
ffectiveness of seasonal inﬂuenza vaccines has been attributable
o mutations associated with egg adaptation (Kishida et al., 2012;
kowronski et al., 2014). The mutations can appear at the initial
tages of candidate vaccine seed virus generation, or even before,
ince egg-propagated isolates are used for seed virus generation.
onitoring the sequences of the surface antigen gene segments at
very step of the reassortment process, starting at the ﬁrst selective
assage, allows for rapid selection of clones with minimal number
f mutations, while discarding clones which have mutations known
o affect antigenicity. Antigenic identity determined by two-way
I assay is currently widely accepted for vaccine candidate charac-
erization (Barr et al., 2010, 2014; Katz et al., 2011). All candidate
accine reassortants listed on WHO  web site as recommended for
se in the current inﬂuenza season (http://www.who.int/inﬂuenza/
accines/virus/en/) passed the two-way HI test. Successful results
f the two-way HI assay for the ﬁnal seed virus conﬁrm that any
utations acquired by the reassortant during egg propagation do
ot affect antigenicity, and that a particular candidate vaccine seed
an be recommended for vaccine production. 8.5 5.9 0
 9.5 6.4 0
One of the major concerns in LAIV production by conventional
reassortment is homogeneity. Since LAIV is produced by biologi-
cal cloning using limiting dilution in eggs, there is a possibility of
obtaining an impure vaccine candidate. To ensure that the ﬁnal can-
didate vaccine seed virus contains a pure genomic constellation, we
developed a real-time RT-PCR assay (Shcherbik et al., 2014a) and
used it to examine all LAIV candidate reassortants. In addition, we
subjected each seed virus to 5 additional egg passages followed
by sequence analysis and real-time RT-PCR to demonstrate the
stability of the vaccine seeds genome composition and sequence
integrity. Sequencing the reassortants after these passages did not
detect any changes in the genomes of any of the reassortants tested,
conﬁrming their genetic stability and suitability as vaccine seed
viruses for manufacturing.
In conclusion, our study demonstrates that the improved proto-
col has certain advantages over the conventional IEM protocol—we
were able to shorten the duration of LAIV generation, precisely
select reassortants with the desired 6:2 genome composition
and without egg-adaptive mutations that often negatively impact
antigenicity. Our new strategy was successfully used to develop
LAIV seed viruses for the 2013/2014, 2014/2015, and 2015/2016
inﬂuenza seasons.
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